Published in Nat Cell Biol on July 01, 2002
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev (2003) 4.89
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell (2005) 3.75
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell (2007) 2.92
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia (2004) 2.60
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 2.52
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res (2004) 2.33
Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res (2003) 2.30
Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am J Pathol (2004) 2.17
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol (2003) 1.99
Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest (2005) 1.98
Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest (2008) 1.88
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest (2011) 1.59
Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs (2010) 1.57
Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res (2010) 1.47
p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol (2004) 1.44
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res (2008) 1.42
Regulation of Smad activities. Biochim Biophys Acta (2006) 1.41
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol (2008) 1.37
Nonlinear optical imaging to evaluate the impact of obesity on mammary gland and tumor stroma. Mol Imaging (2007) 1.36
Small C-terminal domain phosphatase enhances snail activity through dephosphorylation. J Biol Chem (2008) 1.31
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol (2009) 1.23
TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol (2015) 1.23
Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis (2007) 1.23
Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle (2006) 1.21
PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes. J Invest Dermatol (2010) 1.13
Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer (2008) 1.12
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
Normal morphogenesis of epithelial tissues and progression of epithelial tumors. Wiley Interdiscip Rev Syst Biol Med (2011) 1.10
p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res (2006) 1.09
Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol (2005) 1.08
Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell (2006) 1.06
Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res (2011) 1.04
Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis (2011) 1.02
PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma. J Oncol (2010) 1.01
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3β. Sci Rep (2013) 1.00
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res (2005) 1.00
Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J Biol Chem (2009) 1.00
Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett (2012) 0.98
Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski. Mol Biol Cell (2003) 0.97
Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther (2008) 0.96
The tale of transforming growth factor-beta (TGFbeta) signaling: a soigné enigma. IUBMB Life (2009) 0.96
Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene (2010) 0.95
Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev (2013) 0.94
Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression. Oxid Med Cell Longev (2015) 0.91
Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta. Exp Cell Res (2007) 0.90
Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology (2007) 0.89
Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin. Int J Clin Exp Pathol (2012) 0.89
Zyxin is a transforming growth factor-β (TGF-β)/Smad3 target gene that regulates lung cancer cell motility via integrin α5β1. J Biol Chem (2012) 0.89
Ras promotes transforming growth factor-β (TGF-β)-induced epithelial-mesenchymal transition via a leukotriene B4 receptor-2-linked cascade in mammary epithelial cells. J Biol Chem (2014) 0.89
The dual role of Smad7 in the control of cancer growth and metastasis. Int J Mol Sci (2013) 0.88
TGF-beta1-Induced Expression of the Poor Prognosis SERPINE1/PAI-1 Gene Requires EGFR Signaling: A New Target for Anti-EGFR Therapy. J Oncol (2009) 0.88
Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14Ptch(FVB) mice. J Invest Dermatol (2012) 0.86
TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases. J Gastroenterol (2013) 0.86
Cooperative involvement of NFAT and SnoN mediates transforming growth factor-β (TGF-β) induced EMT in metastatic breast cancer (MDA-MB 231) cells. Clin Exp Metastasis (2013) 0.84
The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy. Curr Cancer Drug Targets (2010) 0.83
Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res (2012) 0.83
Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C. Mol Vis (2010) 0.83
Tumor suppressor and oncogene actions of TGFbeta1 occur early in skin carcinogenesis and are mediated by Smad3. Mol Carcinog (2009) 0.83
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis. ISRN Mol Biol (2012) 0.83
Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes. Int J Otolaryngol (2013) 0.82
Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy. Future Oncol (2010) 0.82
The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol (2011) 0.81
Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res (2009) 0.81
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest (2015) 0.81
The Role of TGFβ Signaling in Squamous Cell Cancer: Lessons from Mouse Models. J Skin Cancer (2012) 0.80
miR-148a downregulates the expression of transforming growth factor-β2 and SMAD2 in gastric cancer. Int J Oncol (2016) 0.80
Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients. Mol Cancer (2010) 0.79
NDRG1 attenuates epithelial-mesenchymal transition of nasopharyngeal cancer cells via blocking Smad2 signaling. Biochim Biophys Acta (2015) 0.78
Reversible Human TGF-β Signal Shifting between Tumor Suppression and Fibro-Carcinogenesis: Implications of Smad Phospho-Isoforms for Hepatic Epithelial-Mesenchymal Transitions. J Clin Med (2016) 0.78
Modeling cutaneous squamous carcinoma development in the mouse. Cold Spring Harb Perspect Med (2014) 0.78
The role of endocytic Rab GTPases in regulation of growth factor signaling and the migration and invasion of tumor cells. Small GTPases (2015) 0.78
Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition. J Gynecol Oncol (2013) 0.77
Redox processes inform multivariate transdifferentiation trajectories associated with TGFβ-induced epithelial-mesenchymal transition. Free Radic Biol Med (2014) 0.77
Dual effects of Ral-activated pathways on p27 localization and TGF-β signaling. Mol Biol Cell (2013) 0.75
Identifying new targets in leukemogenesis using computational approaches. Saudi J Biol Sci (2015) 0.75
Cancer Stem Cells: Cellular Plasticity, Niche, and its Clinical Relevance. J Stem Cell Res Ther (2016) 0.75
An Automated High-throughput Array Microscope for Cancer Cell Mechanics. Sci Rep (2016) 0.75
Lgr6 is a stem cell marker in mouse skin squamous cell carcinoma. Nat Genet (2017) 0.75
Antiproliferative and proapoptotic activities of anthocyanin and anthocyanidin extracts from blueberry fruits on B16-F10 melanoma cells. Food Nutr Res (2017) 0.75
miR-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma. Br J Dermatol (2016) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science (2008) 3.78
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet (2003) 3.70
Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol (2007) 2.75
Stem-cell hierarchy in skin cancer. Nat Rev Cancer (2003) 2.36
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet (2008) 2.05
Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat Biotechnol (2002) 2.04
Genomic segmental polymorphisms in inbred mouse strains. Nat Genet (2004) 1.93
Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature (2009) 1.89
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet (2006) 1.79
TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci (2012) 1.74
Mapping segmental and sequence variations among laboratory mice using BAC array CGH. Genome Res (2005) 1.71
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature (2007) 1.54
Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res (2009) 1.51
TGF beta signaling in health and disease. Nat Genet (2004) 1.48
The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol (2008) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes Dev (2004) 1.31
Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol (2013) 1.30
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
Genetic interactions between Pten and p53 in radiation-induced lymphoma development. Oncogene (2003) 1.28
Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res (2003) 1.27
TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets (2006) 1.24
Transforming growth factor-beta1 mediates cellular response to DNA damage in situ. Cancer Res (2002) 1.23
Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci U S A (2013) 1.16
Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun (2012) 1.13
Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. J Invest Dermatol (2004) 1.11
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol (2010) 1.10
The paradoxical TGF-β vasculopathies. Nat Genet (2012) 1.09
Defective retinal vascular endothelial cell development as a consequence of impaired integrin αVβ8-mediated activation of transforming growth factor-β. J Neurosci (2012) 1.08
Genomic approaches to identification of tumour-susceptibility genes using mouse models. Curr Opin Genet Dev (2003) 1.08
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol (2011) 1.08
Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet (2009) 1.06
Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res (2012) 1.05
p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene (2005) 1.04
A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Genetic modifiers interact with maternal determinants in vascular development of Tgfb1(-/-) mice. Hum Mol Genet (2003) 1.03
Mutations of TGFbeta signaling molecules in human disease. Ann Med (2006) 1.03
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res (2005) 1.00
Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 0.98
Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. Genes Dev (2011) 0.98
Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc Natl Acad Sci U S A (2006) 0.97
Developing novel oncolytic adenoviruses through bioselection. J Virol (2003) 0.97
Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res (2011) 0.96
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun (2013) 0.95
Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice. Oncogene (2005) 0.95
Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev (2013) 0.94
Mouse strain-dependent heterogeneity of resting limbal vasculature. Invest Ophthalmol Vis Sci (2004) 0.93
High activity of serum response factor in the mesenchymal transition of epithelial tumor cells is regulated by RhoA signaling. J Biol Chem (2002) 0.92
Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental angiogenesis. Genomics (2005) 0.90
Crosstalk between Pten and Ras signaling pathways in tumor development. Cell Cycle (2005) 0.89
Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility. PLoS One (2012) 0.88
Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus. BMC Genomics (2008) 0.88
TGFbeta inhibition of yolk-sac-like differentiation of human embryonic stem-cell-derived embryoid bodies illustrates differences between early mouse and human development. J Cell Sci (2006) 0.88
The genetics of cancer susceptibility: from mouse to man. Toxicol Pathol (2004) 0.87
Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14Ptch(FVB) mice. J Invest Dermatol (2012) 0.86
Identification of Fetuin-B as a member of a cystatin-like gene family on mouse chromosome 16 with tumor suppressor activity. Genome (2004) 0.85
Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants. J Virol (2003) 0.85
Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc Natl Acad Sci U S A (2012) 0.84
Cancer: new-age tumour suppressors. Nature (2002) 0.83
Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proc Natl Acad Sci U S A (2010) 0.82
Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. Clin Cancer Res (2009) 0.81
Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood (2011) 0.81
The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol (2011) 0.81
Multiple self-healing squamous epithelioma (MSSE): rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology. J Invest Dermatol (2013) 0.79
A sweet link between TGFbeta and vascular disease? Nat Genet (2006) 0.79
Taking thalidomide out of rehab. Nat Med (2010) 0.78
Novel approaches to identify low-penetrance cancer susceptibility genes using mouse models. Recent Results Cancer Res (2003) 0.78
Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. Clin Cancer Res (2013) 0.78
C/EBPδ: friend or foe? a novel role for C/EBPδ in metastasis. EMBO J (2010) 0.76
BMP-9 balances endothelial cell fate. Proc Natl Acad Sci U S A (2013) 0.75
Cancer: dangerous liaisons. Nature (2004) 0.75